FDA Places Clinical Hold on CASI Pharmaceuticals' CID-103 Trial
核心洞察
The FDA has placed a clinical hold on CASI Pharmaceuticals' CID-103, an anti-CD38 (搜索) monoclonal antibody, halting its clinical trial.
The hold was initiated due to unspecified reasons, and CASI Pharmaceuticals is currently seeking clarification from the FDA regarding the concerns.
CID-103 is being developed for the treatment of multiple myeloma (搜索) and other hematological malignancies (搜索), representing a potential setback for the company's pipeline.
The U.S. Food and Drug Administration (FDA) has issued a clinical hold on CASI Pharmaceuticals' investigational drug, CID-103, an anti-CD38 (搜索) monoclonal antibody currently in clinical development. This action effectively suspends the ongoing clinical trial of CID-103, a drug intended for the treatment of multiple myeloma (搜索) and other hematological malignancies (搜索).
CASI Pharmaceuticals is actively engaging with the FDA to understand the specific reasons behind the clinical hold. The company intends to address the FDA's concerns and work towards a resolution that will allow the clinical trial to resume. The company has not yet disclosed the specific reasons for the hold.
CID-103 is designed to target the CD38 (搜索) protein, which is highly expressed on multiple myeloma (搜索) cells and other hematological cancer cells. Monoclonal antibodies targeting CD38 have shown efficacy in treating multiple myeloma, and CID-103 represents CASI Pharmaceuticals' attempt to develop a competitive therapy in this space. The clinical hold introduces uncertainty into the development timeline for CID-103 and its potential to address unmet needs in the treatment of multiple myeloma and related conditions.
The company is working to provide further updates as more information becomes available and as they work with the FDA to resolve the clinical hold.